LEUKAEMIA MICROENVIRONMENT & HIGH RISK CHILDHOOD LEUKAEMIA
With
Associate Professor Laurence Cheung
Curtin University
& Research Lead, Curtin Medical Research Institute,
Western Australia &
Research Lead,
The Kids Research Institute,
Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Associate Professor Laurence Cheung is an exemplary pharmacist-scientist whose research is focused on improving outcomes in children with high-risk leukaemia.
He obtained his Bachelor of Pharmacy degree with First Class Honours from the Curtin University in 2000 and have been a registered pharmacist since 2001. In 2014, he completed the PhD studies at The Kids Research Institute Australia (The Kids) in the area of haematopoiesis and paediatric leukaemia.
He is now an Associate Professor at the Curtin Medical School as well as Curtin Medical Research Institute, and a Co-head of the Leukaemia Translational Research Laboratory at The Kids.
He has attracted over $8.7 million in research funding, including 16 awards as CIA (over $6.1 million). Assoc Prof Cheung was named the 2019 Cancer Council of WA Early Career Cancer Researcher of the Year and received the STEM Early Career Research Award at Curtin University in 2019.
Assoc Prof Cheung enjoys nurturing and motivating the next generation scientists and HDR students and he believes that the true success is about influencing others to achieve their own greatness.
He has supervised two PhD and one Masters students to completion, and is currently supervising 4 PhD students as a Primary Supervisor. In 2023, Assoc Prof Cheung received the Faulty of Health Sciences Teaching Excellence Individual Award for Honours, Postgraduate, or HDR supervision at Curtin University.
Funding sources include: Toby for Childhood Cancer, Cancer Council Western Australia, WA Government
Source: Supplied and adapted
https://orcid.org/0000-0001-6298-5288
-
Stem cells used for age-related macular degeneration
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
-
Novel therapy for pancreatic cancers, targeting molecular foundation
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
-
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
